Tezspire AstraZeneca Pty Ltd
Product name
Tezspire
Sponsor
Accepted date
Jan-2024
Active ingredients
tezepelumab
Proposed indication
As an add-on maintenance treatment in patients with severe asthma.
Application type
A (new medicine)
Publication date
Jan-2024